MC

463

-1.46%↓

SANES

9.494

-2.82%↓

SAF

283.9

-3.4%↓

BBVA

18.25

-2.51%↓

BNP

83.22

-1.81%↓

MC

463

-1.46%↓

SANES

9.494

-2.82%↓

SAF

283.9

-3.4%↓

BBVA

18.25

-2.51%↓

BNP

83.22

-1.81%↓

MC

463

-1.46%↓

SANES

9.494

-2.82%↓

SAF

283.9

-3.4%↓

BBVA

18.25

-2.51%↓

BNP

83.22

-1.81%↓

MC

463

-1.46%↓

SANES

9.494

-2.82%↓

SAF

283.9

-3.4%↓

BBVA

18.25

-2.51%↓

BNP

83.22

-1.81%↓

MC

463

-1.46%↓

SANES

9.494

-2.82%↓

SAF

283.9

-3.4%↓

BBVA

18.25

-2.51%↓

BNP

83.22

-1.81%↓

Search

Eurazeo SE

Открыт

СекторФинансы

37.62 -4.47

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

37.66

Макс.

39.54

Ключевые показатели

By Trading Economics

Доход

-309M

Продажи

372M

283M

Дивидендная доходность

6.36

Рентабельность продаж

347.853

Сотрудники

438

EBITDA

-256M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+85.04% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

6.36%

4.84%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-323M

2.6B

Предыдущая цена открытия

42.09

Предыдущая цена закрытия

37.62

Новостные настроения

By Acuity

100%

0%

425 / 441 Рейтинг в Finance

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Eurazeo SE График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 мар. 2026 г., 23:47 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 мар. 2026 г., 22:55 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 мар. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 мар. 2026 г., 23:50 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 мар. 2026 г., 23:37 UTC

Обсуждения рынка

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Global Equities Roundup: Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 мар. 2026 г., 22:40 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 мар. 2026 г., 22:23 UTC

Обсуждения рынка

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 мар. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 мар. 2026 г., 22:18 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 мар. 2026 г., 22:15 UTC

Приобретения, слияния, поглощения

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 мар. 2026 г., 22:08 UTC

Обсуждения рынка

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 мар. 2026 г., 21:10 UTC

Главные новостные события

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка
Отчет
Главные новостные события

Basic Materials Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Eurazeo SE Прогноз

Целевая цена

By TipRanks

85.04% рост

Прогноз на 12 месяцев

Средняя 72.5 EUR  85.04%

Максимум 85 EUR

Минимум 60 EUR

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Eurazeo SE на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

1

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

62.3 / N/AПоддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

425 / 441Рейтинг в Финансы

Новостные настроения

Сильные свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Eurazeo SE

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in mid-market and listed public companies. The company invest in equity in the small-mid and Mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, SMEs, high growth companies, and real estate management and investment activities. It does not have any restrictions regarding the sectors in which it invests but prefers to invest in smart cities, services, leisure and mobility, real estate, fintech, investment activities, distribution, industry, luxury, consumer goods, business services, consumer and retail brands, and health sectors. The firm seeks to invest in consumer brands with a focus on beauty, personal care, household care, juvenile products, apparel, wellness, accessories, home, jewellery, leisure, health, fitness, beverage, and food companies based in United States and Europe. It typically invests in companies with a differentiated concept and global growth potential. The firm identifies companies upstream, carefully selecting them primarily from sectors driven by digital transformation and focusing on changes in lifestyle and consumption (mobility, online buying, collaboration models, etc. The firm invests in large properties in need of restructuring; residential, commercial, and office development projects; and companies with real estate assets in Western Europe. It primarily invests in United States, France, Italy, North America and other European countries. It seeks to invest between "50 million ($54.35 million) to "250 million ($271.77 million) in small mid buyout business. It seeks to invest between "25 million ($27.18 million) to "100 million ($108.71 million) in growth business. It seeks to invest between "10 million ($10.82 million) and "40 million ($43.82 million) in the fields of healthcare research. It seeks to invests between equity investment between "1 million ($1.17 million) and "559.01 mil
help-icon Live chat